Clinical Trial Update: Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing six months versus twelve months of trastuzumab with docetaxel after FEC as adjuvant therapy for node-positive breast cancer has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Taxotere (docetaxel)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED